See more
Is MannKind a good stock to Buy?
MannKind has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
What does MannKind Corporation do?
As a biopharmaceutical company focused on creating cutting-edge therapies and technologies for patients with diabetes and orphan lung diseases, MannKind is on a mission to help people take control of their health.
Who founded mannkind?
Alfred E. MannMannKind Corporation / FounderAlfred E. Mann, also known as Al Mann, was an American physicist, inventor, entrepreneur, and philanthropist. Wikipedia
Is inhaled insulin available?
Inhaled Insulin Today In June 2014, the FDA approved Afrezza. It's an inhaler with pre-measured, rapid-acting insulin you use before meals. It's not for diabetes emergencies such as diabetic ketoacidosis (DKA). Common side effects of inhaled insulin are low blood sugar, a cough, and a scratchy or sore throat.
Is afrezza still on the market?
No. Afrezza insulin is not discontinued and is available by prescription for adults with type 1 or type 2 diabetes.
What company makes afrezza?
Mannkind's Danbury plant manufactures Afrezza, a rapid-acting insulin therapy.
How effective is afrezza?
Effectiveness. Afrezza and Apidra haven't been directly compared in clinical studies. However, studies have found both drugs to be effective in helping manage blood sugar in adults with type 1 or type 2 diabetes.
How fast does afrezza work?
WHAT DOES FAST IN, FAST OUT MEAN? Afrezza® is most active between 35–45 minutes and stops lowering blood glucose after 1.5 to 3 hours, depending on the dose.
Should I buy or sell MannKind stock right now?
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. There are currently 3 buy rat...
What is MannKind's stock price forecast for 2022?
3 brokers have issued twelve-month target prices for MannKind's shares. Their forecasts range from $6.00 to $6.00. On average, they predict MannKin...
How has MannKind's stock performed in 2022?
MannKind's stock was trading at $4.37 at the beginning of 2022. Since then, MNKD shares have decreased by 0.5% and is now trading at $4.35. View t...
When is MannKind's next earnings date?
MannKind is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022. View our earnings forecast for MannKind .
How were MannKind's earnings last quarter?
MannKind Co. (NASDAQ:MNKD) released its earnings results on Thursday, May, 5th. The biopharmaceutical company reported ($0.10) earnings per share f...
Who are MannKind's key executives?
MannKind's management team includes the following people: Dr. Michael E. Castagna Pharm.D. , CEO & Director (Age 45, Pay $1.12M) Mr. Steven B. B...
Who are some of MannKind's key competitors?
Some companies that are related to MannKind include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Regeneron Pharmaceu...
What other stocks do shareholders of MannKind own?
Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BH...
What is MannKind's stock symbol?
MannKind trades on the NASDAQ under the ticker symbol "MNKD."
Is MANNKIND Stock a good buy in 2022, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering ( NASDAQ : MNKD ) stock is to Buy MNKD stock. Out of 1 analyst , 0 ( 0% ) are recommen...
What is MNKD's earnings growth forecast for 2022-2024?
( NASDAQ : MNKD ) MANNKIND 's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average f...
What is MNKD's revenue growth forecast for 2022-2024?
( NASDAQ : MNKD ) MANNKIND 's forecast annual revenue growth rate of 49.52% is forecast to beat the US Biotechnology industry's average fore...
What is MNKD's forecast return on assets (ROA) for 2022-2025?
(NASDAQ: MNKD) forecast ROA is 27.85%, which is higher than the forecast US Biotechnology industry average of 21.58%.
What is MNKD's Price Target?
According to 1 Wall Street analyst that have issued a 1 year MNKD price target, the average MNKD price target is $6.00 , with the highest M...
What is MNKD's Earnings Per Share (EPS) forecast for 2022-2024?
(NASDAQ: MNKD) MANNKIND's current Earnings Per Share (EPS) is -$0.37. On average, analysts forecast that MNKD's EPS will be -$0.34 for 2022, with t...
What is MNKD's forecast return on equity (ROE) for 2022-2025?
(NASDAQ: MNKD) forecast ROE is -37%, which is considered weak.
MNKD earnings per share forecast
What is MNKD 's earnings per share in the next 3 years based on estimates from 4 analyst s?
MNKD revenue forecast
What is MNKD 's revenue in the next 3 years based on estimates from 3 analyst s?
MNKD revenue growth forecast
How is MNKD forecast to perform vs Biotechnology companies and vs the US market?
MannKind Corp Stock Forecast
Is MannKind Corp Stock Undervalued? The current MannKind Corp [ MNKD] share price is $3.86. The Score for MNKD is 58, which is 16% above its historic median score of 50, and infers lower risk than normal.
Stock Predictions
Is MannKind Corp stock public? Yes, MannKind Corp is a publicly traded company.
Stock Price Forecast
The 4 analysts offering 12-month price forecasts for MannKind Corp have a median target of 5.75, with a high estimate of 8.00 and a low estimate of 5.00. The median estimate represents a +112.18% increase from the last price of 2.71.
Analyst Recommendations
The current consensus among 4 polled investment analysts is to Buy stock in MannKind Corp. This rating has held steady since February, when it was unchanged from a Buy rating. Move your mouse over past months for detail
Why are people not buying Mannkind?
In that case, they are not buying Mannkind because the equity is a good investment, but because they need to do something to avoid the feeling of missing out.
How to measure market sentiment?
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Does Mannkind stock have volatility?
Mannkind Corp's implied volatility exposes the market's sentiment of Mannkind Corp stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Mannkind Corp's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Mannkind Corp stock will not fluctuate a lot when Mannkind Corp's options are near their expiration.
Does Mannkind Corp have a cover story?
The number of cover stories for Mannkind Corp depends on current market conditions and Mannkind Corp's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Mannkind Corp is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Mannkind Corp's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
How does MarketBeat calculate stock ratings?
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Does Mannkind outperform?
MarketBeat users like MannKind stock less than the stock of other Medical companies. 60.28% of MarketBeat users gave MannKind an outperform vote while medical companies recieve an average of 67.30% outperform votes by MarketBeat users.
How much did Mannkind stock fall in 2021?
The MannKind Corporation stock price fell by -2.00% on the last day (Thursday, 8th Jul 2021) from $4.99 to $4.89. and has now fallen 5 days in a row. During the day the stock fluctuated 4.88% from a day low at $4.71 to a day high of $4.94. The price has been going up and down for this period, and there has been a 8.19% gain for the last 2 weeks. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -316 thousand shares and in total, 3 million shares were bought and sold for approximately $13.20 million.
What is Mannkind Corporation?
MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes patients in the United States. Its approved product is AFREZZA, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. MannKind Corporation has license and collaboration agreement with Sanofi-Aventis Deutschland GmbH for the development of AFREZZA.... Read more
Is Mannkind stock a sell signal?
The MannKind Corporation stock holds a sell signal from the short-term moving average ; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. On further gains, the stock will meet resistance from the short-term moving average at approximately $5.24. On a fall, the stock will find some support from the long-term average at approximately $4.44. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. Furthermore, there is a buy signal from the 3 months Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Thursday, July 01, 2021, and so far it has fallen -10.77%. Further fall is indicated until a new bottom pivot has been found. Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.
Is MannKind Corporation stock A Buy?
MannKind Corporation holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
